Amneal Pharmaceuticals, Inc. Q1 FY2026 earnings call

• Announced acquisition of Kashiv BioSciences, creating a fully integrated global biosimilars leader. • Q1 results showed strong top and bottom line growth. • Plans to have 6 commercial biosimilars by 2027, 6 or more additional approvals by 2030. • Expect $400 million to $500 million in cumulative financial synergies from acquisition. • Envision Amneal 2030 as a larger, more diversified biopharmaceutical company with biosimilars and specialty products.

Q1 marked another consecutive quarter of strong top and bottom line growth with revenue up 4%, adjusted EBITDA up 19% and EPS up 29%. Affordable Medicines revenue was $423 million, grew 2%, driven by key women's health and ADHD products. Specialty revenue was $133 million, grew 23%. AvKARE revenues were $166 million, declined by $6 million or 4%.

• Raised stand-alone guidance for 2026. • Combined view including Kashiv largely unchanged aside from near-term transaction and integration costs, maintaining higher adjusted EBITDA and EPS outlook. • Expect combined company to continue growth in top and bottom line performance, with revenues expected to grow by approximately $1.2 billion or 40% over 2026 and EPS up by approximately $0.70 or 70% over 2026 by 2030. • Maintain disciplined financial profile with path to deleverage to below 3x by 2028.

• Execution risk in integration of Kashiv BioSciences. • Competitive landscape in biosimilars with potential for multiple players. • Regulatory approvals and timing for biosimilar launches. • Macroeconomic factors could impact financial performance.

Q: Congrats on the deal. Commercial strategy for expanded portfolio, international biosimilars, and what's exciting about new combined company?

A: Discussed portfolio mix, U.S. commercialization, international strategy, and excitement about core business, specialty brands, GLP-1 partnership, and biosimilars.

Q: Capacity scaling, gross margin profile?

A: Kashiv has capacity scaling plans, spending on CapEx, and gross margin expected to expand from 43% in 2025 to around 45% in 2026 with further growth potential.

Q: Insider ownership of Kashiv, long-term revenue EBITDA targets, revenue base from biosims?

A: Addressed insider ownership, rationale for long-term targets, and revenue from biosims.

Q: Competitive landscape on biosimilars, lanreotide opportunity?

A: Discussed competitive landscape with few vertically integrated players, and lanreotide market dynamics and approval timeline.

Q: Operational complexities of acquisition, 2027 EBITDA guidance?

A: Addressed operational complexities of vertical integration, and EBITDA guidance and growth expectations.